



The Medicines Patent Pool Foundation

Governance Board Meeting Chairman's Summary

18 November 2015



Attendees:

Board Members: Dr. Charles Clift, Dr. Bernard Pécoul, Dr. Sigrun Møgedal, Dr. Anban Pillay, Ms. Anna Żakowicz, Ms. Jayashree Watal, Ms. Claudia Chamas, Dr. Brian Tempest.

MPP staff: Greg Perry (Executive Director), Chan Park (General Counsel), Sandeep Juneja (Business Development Director), Maica Trabanco (Associate Counsel), Esteban Burrone (Head of Policy), Katie Moore (Head of Communications), Alnaaze Nathoo (Strategy and Operations Manager), José Imbernon (Finance and HR Manager) and Ms. Asma Rehan (Operations Officer).

The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) for its report assessing the final results of negotiations between the MPP and Bristol-Myers Squibb (BMS) on a licence agreement for daclatasvir. The Board has reviewed the EAG report and the proposed Licence and Technology Transfer Agreement between the MPP and BMS. The Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as defined in its Statutes and Memorandum of Understanding with UNITAID, and represents a significant improvement over the status quo. Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with BMS to formalize the collaboration. The Board further recommends that the MPP continue to seek the inclusion of all people living with HCV in low- and middle-income countries in this and other future collaborations.